Noble Financial Weighs in on Nutriband FY2025 Earnings

Nutriband Inc. (NASDAQ:NTRB) – Equities researchers at Noble Financial issued their FY2025 earnings estimates for Nutriband in a research note issued to investors on Wednesday, January 22nd. Noble Financial analyst R. Leboyer expects that the company will earn ($0.60) per share for the year. Noble Financial currently has a “Outperform” rating and a $13.00 price target on the stock. Noble Financial also issued estimates for Nutriband’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.45 EPS and FY2028 earnings at $3.66 EPS.

Nutriband Stock Up 34.9 %

NTRB opened at $9.90 on Friday. The business’s fifty day simple moving average is $4.59 and its 200 day simple moving average is $5.44. Nutriband has a 52 week low of $2.22 and a 52 week high of $11.78. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The stock has a market cap of $109.99 million, a PE ratio of -13.94 and a beta of 0.99.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.12) EPS for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.